Projects funded by the NCN
New opportunities for use of PERK kinase inhibitors in eIF2alfa factor-dependant signalling pathway in antitumor therapy
2015/19/N/NZ3/00055
Keywords:
tumor PERK kinase eukaryotic initiation factor 2 - eIF2alfa PERK kinase inhibitors antitumor therapy
Descriptors:
- NZ3_3: Apoptosis
- NZ3_7: Signal transduction
- NZ3_1: Cell biology
Panel:
NZ3 - Cellular and developmental biology: cell biology, developmental biology, ageing biology, neurobiology
Host institution :
Uniwersytet Medyczny w Łodzi, Wydział Lekarski
woj. łódzkie
Principal investigator (from the host institution):
Number of co-investigators in the project: 2
Call: PRELUDIUM 10 - announced on 2015-09-15
Amount awarded: 143 000 PLN
Project start date (Y-m-d): 2016-08-09
Project end date (Y-m-d): 2020-08-08
Project duration:: 48 months (the same as in the proposal)
Project status: Project settled
Project description
Download the project description in a pdf file
Note - project descriptions were prepared by the authors of the applications themselves and placed in the system in an unchanged form.